Lynn Zhang
Family · Los Angeles, CANPI 1528289501
Payments from drug & device makers
Across 70 payments — averaging $119.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Johnson & Johnson$1K
- Viiv Healthcare Company$1K
- AbbVie$749
- Incyte Corporation$390
- Astellas Pharma US Inc$373
- plus $3K from 16 others
What the payments were for
- Food & beverage$8,345100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 16 | $1,610 |
| Johnson & Johnson(2 entities) | 10 | $1,270 |
| Viiv Healthcare Company | 9 | $1,079 |
| AbbVie | 6 | $749 |
| Incyte Corporation | 3 | $390 |
| Astellas Pharma US Inc | 3 | $373 |
| Alkermes, Inc. | 3 | $340 |
| AstraZeneca | 3 | $338 |
| Neurocrine Biosciences, Inc. | 2 | $314 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $266 |
| Teva Pharmaceuticals USA, Inc. | 2 | $240 |
| Bayer | 1 | $145 |
| Madrigal Pharmaceuticals | 1 | $140 |
| Braeburn Inc. | 1 | $139 |
| Napo Pharmaceuticals Inc | 1 | $128 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Indivior Inc. | 1 | $125 |
| EMD Serono, Inc. | 1 | $122 |
| Lundbeck LLC | 1 | $121 |
| Puma Biotechnology, Inc. | 1 | $118 |
| Syndax Pharmaceuticals, Inc. | 1 | $115 |
| Alnylam Pharmaceuticals Inc. | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,345 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $34,477 |
| Icosapent Ethyl | 13 | $1,926 |
| Quetiapine Fumarate | 42 | $891 |
| Valproic AcidValproic Acid (As Sodium Salt) | 13 | $702 |
| Kapspargo SprinkleMetoprolol Succinate | 20 | $631 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $586 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $438 |
| Lithium Carbonate | 13 | $258 |
| Benztropine Mesylate | 15 | $220 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 24 | $215 |
| Risperidone | 23 | $184 |
| Propranolol Hcl | 12 | $178 |
| Haloperidol | 12 | $167 |
| Levothyroxine Sodium | 14 | $149 |
| Atorvastatin Calcium | 18 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,270 | $34,47714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Los Angeles
- Annette ShonLos Angeles$406K
- Phyllis CasonLos Angeles$187K
- Theodore SolomonLos Angeles$131K
- Angela SarffLos Angeles$51K
- Karla MenjivarLos Angeles$36K
- Janet GripshoverLos Angeles$30K
- Jualynda SmithLos Angeles$28K
- Phoebedel ReyesLos Angeles$26K
- Lori RobertsonChino Hills$475K
- Nancy GardettoSan Diego$394K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.